JUVE Patent

Nicola Dagg


Kirkland & Ellis

Kirkland & Ellis International LLP
EC3A 8AF London
United Kingdom
phone_icon Created with Sketch. +44 20 7469 2150
envelope_icon Created with Sketch. nicola.dagg@kirkland.com

Expertise

About Nicola Dagg

Nicola Dagg is a partner in the IP litigation team in the London office of Kirkland & Ellis International LLP. Nicola’s practice spans four areas:

►(1) strategic life sciences patent and product lifecycle advice;

►(2) patent litigation;

►(3) co-ordinating global IP enforcement/defence cases; and

►(4) standard essential patent (SEP) and FRAND disputes. Nicola has tried over 20 cases.

Nicola has extensive experience in pharmaceutical and biologics patent litigation including blockbuster small molecule litigation against generic companies, biologics and biosimilar litigation, antibodies, immunotherapies, genetics, vaccines, diagnostics and gene therapies. Nicola also acts in market leading SEP essentiality, validity and global FRAND adjudication litigation in the tech sector. Having served as UK and European/global coordinating counsel for numerous strategic IP litigation cases and drawing on more than 24 years of legal, IP, life sciences and tech experience she helps clients solve their most pressing global challenges.

Nicola writes and speaks extensively on intellectual property litigation. Chambers Global 2020 recognises Nicola as a “pre-eminent” litigator who is “fantastic – extremely strategic, laser-focused and gets the right results for her clients”. In their 2019 directory IAM Patent 1000 describe her as “fantastic – the driving force in what is one of the great success stories in recent years” and acknowledge her “impressive” team-building and client-handling skills.

Awards

  • “Client Service All-Star” in 2020 by BTI Consulting Group
  • Intellectual Property Lawyer of the Year 2020 by Benchmark Litigation
  • One of the “Top 250 Women in IP” in the 2020 Managing Intellectual Property list
  • One of the “WIPR Leaders 2020” by World Intellectual Property Review (WIPR)
  • Lawyer of the Year 2017 for Life Sciences (Patent Litigation) by Wo’s Who Legal
  • One of the 10 “Most Highly Regarded Individuals” in Europe by Who’s Who Legal: Patents 2016
  • One of the “Top 50 women lawyers in London” in the 2015 Super Lawyers list
  • Leading IP partner in Chambers Global, Chambers UK and Legal 500
  • Listed as an expert in each of Patent Lawyers, Life Sciences patent litigation and as a Thought Leader for life sciences by Who’s Who Legal
  • Consistently recognized as a gold-ranked patent litigator by IAM Patent 1000

Publications

  • Dagg, N., Baldwin S., Coltart, K., and Shandler, B. (2021) “Patent Litigation 2021: Trends and Developments”, Chambers and Partners Practice Guides
  • Dagg, N., Lim, D., Baldwin, S., and Bornstein, G. (2020) “Trade Secrets 2020: Law and Practice”, Chambers and Partners Practice Guides
  • Dagg, N., Lim, D., Shandler, B., and Kritharidis, A. (2020) “Patent Litigation 2020: Trends and Developments”, Chambers and Partners Practice Guides
  • Dagg, N., Coltart, K., Lim, D., and Ooi, J. (2019) “Patent Litigation 2019: Trends and Developments”, Chambers and Partners Practice Guides
  • Dagg, N., Baldwin, S., and Rollins, T. (2017) “From Takeda to Teva v Merck: Are we treading the right path on combination products SPC’s? (Part 2 of 2)”, European Intellectual Property Review
  • Dagg, N., Baldwin, S., and Rollins, T. (2017) “The definition of product in the SPC Regulation: What’s in a name? (Part 1 of 2)” European Intellectual Property Review
  • Dagg, N. (2014) UK chapter in “Copyright litigation - Jurisdictional comparisons 2nd edition”, Thomson Reuters
  • Dagg, N. (2013) “Second medical use”, The International Who’s Who of Patent Lawyers
  • Dagg, N. (2010) UK chapter in “Copyright Litigation – Jurisdictional comparisons”, Thomson Reuters
  • Video Interview: Regulatory issues key for life sciences in Brexit debate. Life Sciences Review (25 August 2017)
  • Video Interview: Life Sciences Patent Network Europe, Life Sciences Review (20 December 2016)

More experts at Kirkland & Ellis